Equal Opportunities in Academic Careers? How Mid-Career Scientists at ETH Zurich Evaluate the Impact of Their Gender and Age

Gender equality is essential to social justice and sustainable development in the higher education sector. An important aspect thereof is to promote equal opportunities for academic careers. This study investigates the current situation and possibilities for improvement in this regard from the perspectives of mid-career scientists in a sustainability-oriented university department. A survey of scientists from the postdoctoral to adjunct professor level (N = 82) in the Department of Environmental Systems Science (D-USYS) of ETH Zurich (Swiss Federal Institute of Technology Zurich) was thus conducted to investigate judgements, experiences, and ideas for improvement concerning equal career opportunities. About 90% of the respondents perceived no disadvantages based on gender, ethnicity, race, or faith. However, about 30% felt disadvantaged due to their age. Comments revealed not a single case in which latter disadvantages were based on prejudice. Instead, ETH-wide or national age and time-based restrictions for certain positions caused the inequality perceptions. Furthermore, comments indicated that these restrictions can disadvantage scientists taking care of children. Some participants suggested a revision or removal of corresponding rules. Further suggestions included an improved availability of childcare places. ETH Zurich recently undertook great efforts to provide excellent and affordable childcare services, increasing the number of available places by about 30% in the year following this survey

Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations

Background: Noonan syndrome, cardio-facio-cutaneous syndrome (CFC) and Costello syndrome constitute a group of developmental disorders with an overlapping pattern of congenital anomalies. Each of these conditions can be caused by germline mutations in key components of the highly conserved Ras-MAPK pathway, possibly reflecting a similar pathogenesis underlying the three disorders. Germline mutations in KRAS have recently been identified in a small number of patients with Noonan syndrome and CFC. Methods and results: 260 patients were screened for KRAS mutations by direct sequencing. Overall, we detected KRAS mutations in 12 patients, including three known and eight novel sequence alterations. All mutations are predicted to cause single amino acid substitutions. Remarkably, our cohort of individuals with KRAS mutations showed a high clinical variability, ranging from Noonan syndrome to CFC, and also included two patients who met the clinical criteria of Costello syndrome. Conclusion: Our findings reinforce the picture of a clustered distribution of disease associated KRAS germline alterations. We further defined the phenotypic spectrum associated with KRAS missense mutations and provided the first evidence of clinical differences in patients with KRAS mutations compared with Noonan syndrome affected individuals with heterozygous PTPN11 mutations and CFC patients carrying a BRAF, MEK1 or MEK1 alteration, respectively. We speculate that the observed phenotypic variability may be related, at least in part, to specific genotypes and possibly reflects the central role of K-Ras in a number of different signalling pathways